share_log

Teva Announces Launch Of The First And Only Generic Version Of Sandostatin LAR Depot, In The U.S.

テバは、米国でサンドスタチンLARデポの初の唯一のジェネリック版の発売を発表

Benzinga ·  10/01 08:31
  • This first-to-market launch showcases Teva's proven strengths in complex generic formulations and enhances Teva's strategic goal of sustaining a generic powerhouse.
  • Octreotide acetate for injectable suspension is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome.

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and only generic version of Sandostatin1 LAR Depot, in the United States.

Octreotide acetate for injectable suspension (the generic version of Sandostatin LAR Depot) is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome. Please see the below for more information.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする